Nilotinib Zentiva Pharma Uk (Nilotinib)

Nilotinib works by selectively inhibiting the BCR‑ABL tyrosine kinase, the abnormal enzyme that drives CML. By blocking the ATP‑binding site of BCR‑ABL, it stops downstream signaling that promotes leukemic cell growth. The drug also blocks related kinases like c‑KIT and PDGFR, enhancing its antileukemic activity.

The dose of Nilotinib is individualized and set by the prescribing physician based on the patient’s disease phase, prior therapy, and overall health. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is contraindicated during pregnancy, and women of childbearing potential must use effective contraception. Breastfeeding is not recommended while taking Nilotinib because the drug can be excreted in milk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to Nilotinib is imatinib, the first‑generation BCR‑ABL inhibitor. Nilotinib is a second‑generation agent with higher potency and activity against many imatinib‑resistant BCR‑ABL mutations. It often achieves faster and deeper molecular responses, though it may carry a different safety profile, including a higher risk of cardiovascular events.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Nilotinib is taken orally as a tablet, usually with a low‑fat meal or on an empty stomach as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed. Patients should follow the specific timing instructions provided by their healthcare professional.

Serious risks include cardiovascular events such as arterial occlusive disease or myocardial infarction, QT‑interval prolongation that can lead to arrhythmias, pancreatitis, and severe liver injury. Patients should report chest pain, palpitations, sudden abdominal pain, jaundice, or any signs of allergic reaction promptly.

Nilotinib should not be used by individuals with known hypersensitivity to the drug or any of its components. It is also contraindicated in pregnant women and should be avoided in patients with uncontrolled infections, severe hepatic impairment, or a history of significant cardiovascular disease unless the benefits outweigh the risks.